UPDATE: Piper Jaffray Raises PT on NuVasive to $42

Piper Jaffray is out with its report today on NuVasive NUVA, raising its PT from $39 to $42. In a note to clients, Piper Jaffray writes, "We expect that in a stabilizing spine market the stock will continue to outperform relative to management guidance and Street estimates. We reiterate our Overweight rating on NUVA, upping out target from $39 to $42, and view the stock as attractively valued at current levels." Shares of NUVA closed Monday at $32.36.